3 Results for "

intracellular pattern recognition receptors

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "intracellular pattern recognition receptors" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P3496
CAS No.: 1322711-38-5
Target:  

Pyroptosis

Research Areas:  

Inflammation/Immunology

Pep19-2.5 is an synthetic and antitoxin peptide, blocks the intracellular endotoxin signaling cascade. Pep19-2.5 inhibits signaling of lipopeptides (LP) and lipopolysaccharides (LPS) mediated by transmembrane and cytosolic pattern recognition receptors (PRRs). The signaling cascades lead to inflammation and cell pyroptosis .
loading...
    loading...
Cat. No.: HY-147339
CAS No.: 3047739-39-6
Target:  

DNA/RNA Synthesis

Research Areas:  

Others

M7G (3'-OMe-5') pppA (2'-OMe) is a modified cap analog. M7G (3'-OMe-5') pppA (2'-OMe) enhances the stability and translation efficiency of mRNA by maintaining the correct orientation of the mRNA cap, promoting cap-dependent translation initiation, and mimicking the Cap-1 structure to reduce immunogenicity. M7G (3'-OMe-5') pppA (2'-OMe) can be used in molecular biology research, vaccine development, and gene therapy applications .
loading...
    loading...
Cat. No.: HY-L237
338 compounds

Pattern Recognition Receptors (PRRs) are a crucial class of protein molecules expressed in cells of the innate immune system. The core function of Pattern Recognition Receptors is to recognize Pathogen-Associated Molecular Patterns (PAMPs) and Damage-Associated Molecular Patterns (DAMPs). Upon recognizing and binding to PAMPs or DAMPs, PRRs rapidly initiate intracellular signaling pathways (such as the NF-κB, IRF, and inflammasome pathways). This triggers the production of inflammatory factors, chemokines, and type I interferons, thereby initiating inflammatory responses to eliminate pathogens or repair damage. PRRs represent the body's first line of defense against infection, and the rapidity and broad specificity of their response are crucial for host survival. However, aberrant activation of PRR signaling is also a cause of many chronic inflammatory diseases, autoimmune disorders, and neurodegenerative diseases. Therefore, precisely regulating PRR activity has become a key therapeutic strategy for these conditions.

MCE has cataloged 338 inhibitors targeting key PRRs, such as NLRs, TLRs, C-type Lectin Receptors (CLRs), and cGAS, to support drug discovery efforts for chronic inflammatory diseases.